The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study.
Steven I. Sherman
Consultant or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis
Honoraria - Exelixis
Ezra E.W. Cohen
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Biodesix
Patrick Schoffski
Consultant or Advisory Role - Exelixis
Honoraria - Exelixis
Research Funding - Exelixis
Rossella Elisei
Consultant or Advisory Role - Exelixis
Honoraria - Exelixis
Martin Schlumberger
Consultant or Advisory Role - Exelixis (U)
Lori J. Wirth
No relevant relationships to disclose
Milan Mangeshkar
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Dana T. Aftab
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Douglas O. Clary
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Marcia S. Brose
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis